Dow Dips Over 500 Points; US GDP Growth Misses Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 25 2024
0mins
Source: earning
- Stock Market Performance: U.S. stocks traded lower, with the Dow Jones falling over 500 points, NASDAQ down by 2.16%, and S&P 500 dropping 1.37%.
- Top Headline: The U.S. economy grew by 1.6% in Q1, a slowdown from the previous quarter's 3.4% growth, below analysts' expectations of 2.5%.
- Equities Trading UP: Stocks like Safe & Green Holdings Corp., Barfresh Food Group, and Processa Pharmaceuticals saw significant increases.
- Equities Trading DOWN: Companies like Hanryu Holdings, Huize Holding Limited, and Chicken Soup for the Soul Entertainment experienced notable declines.
- Commodities and Global Markets: Oil prices rose, gold and silver traded up, European shares were mixed, and Asian markets closed mostly higher.
Analyst Views on PCSA
Wall Street analysts forecast PCSA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PCSA is 1.00 USD with a low forecast of 1.00 USD and a high forecast of 1.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 3.710
Low
1.00
Averages
1.00
High
1.00
Current: 3.710
Low
1.00
Averages
1.00
High
1.00
About PCSA
Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of Next Generation Cancer therapy (NGC) small molecules. The three NGC treatments in its pipeline are NGC-Capecitabine (NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem) and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri) and two non-oncology drug assets are PCS12852, and PCS499. NGC-Cap is a combination of PCS6422 and capecitabine, capecitabine being the oral prodrug of the cancer drug 5-fluorouracil.PCS3117 is an oral analog of gemcitabine that is converted to its active metabolite by a different enzyme system than gemcitabine. PCS11T is a prodrug of the active metabolite of irinotecan (SN-38). PCS12852 is a specific and potent 5HT4 agonist that is in Phase IIB and is a potential treatment for diabetic gastroparesis patients. PCS499 is a drug that can be used to treat unmet medical needs and conditions caused by multiple pathophysiological changes.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
